END-TO-END AMSC DELIVERY
The Revalyxis™ Platform
A licensable technology platform that sources, isolates, expands and delivers clinical-grade amniotic mesenchymal stem cells. One investment enables unlimited parallel pharmaceutical partnerships.
Source
01
Isolate
02
Expand
03
Deliver
04
01
Source
Post-birth amniotic fluid, ethically collected from consented donors - no fetal tissue, no invasive procedures. We ensure the highest ethical standards while maintaining biological integrity.
Our collection process is standardized and patented, providing a reliable and sustainable foundation for cellular therapies. This ensures every batch meets rigorous clinical requirements.
02
Isolate
Proprietary cell separation workflows producing natal, biologically early-stage MSCs. Our unique methods preserve the youthful characteristics of the cells for superior performance.
By isolating specifically for amniotic mesenchymal stem cells, we achieve high purity and potency levels. This precision is critical for effective pharmaceutical applications.
03
Expand
Scalable culture protocol for AMSC proliferation, potency, and yield - with consistent donor-to-donor quality. Our technology enables massive scale without loss of function.
The Revalyxis platform automates the expansion phase, ensuring reproducibility and reducing time-to-clinic. This consistency is the hallmark of our licensable technology.
04
Deliver
Quality compatible formulation and cryopreservation supplied to pharma and biotech partners. We provide ready-to-use cellular matter for immediate integration into workflows.
Our delivery network ensures that materials reach partners in optimal condition. This end-to-end solution bridges the gap between lab research and global therapy.
Cell Banking Programme
1
Primary Bank
Initial isolation and characterization of AMSCs from screened donors.
2
Working Bank
Expansion under controlled conditions to produce standardized lots.
3
Distribution Bank
Final formulation, cryopreservation, and logistics for delivery.
Accelerate Your Therapeutic Pipeline
The Revalyxis™ platform offers pharmaceutical and biotechnology partners a streamlined, ethical path to high-potency AMSC delivery. Our licensing models are engineered to fast-track development cycles by providing direct access to patented isolation and large-scale expansion technologies.
- Ethical Sourcing: Non-invasive, consented donor materials maintaining biological integrity.
- Proven Scalability: Patented workflows for industrial-grade cell yields.
- Clinical Readiness: Comprehensive regulatory documentation and data support.
- Strategic Distribution: Direct integration with global distribution bank logistics.
5
Partnerships
100%
Compliant
99.9%
Isolation Purity